ABBVIE Aktie

 

The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position....

– Severino joins Sarepta's Board of Directors – Doug Ingram to retire from SareptaCAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta's Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to Tessera, he served as Vice Chairman and President at AbbVie, where he was responsible for research and development and the corporate strategy office. During his tenure at AbbVie, he oversaw a rapid expansion of AbbVie's pipeline and built critical new capabilities in areas such as genetics and genomics, computational biology, and precisio...

Nach dem Sprung über die 200-Tage-Linie setzte AbbVie den Aufwärtstrend fort und korrigierte zuletzt bis an die 20-Tage-Linie. Dort stabilisierte sich der Kurs, während die jüngsten Hochs das kurzfristige Chartbild prägen....

Both have very promising futures....

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Media Release...

ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies....

It looks like a great buy-and-hold option....

AbbVie (ABBV) closed at $256.18 in the latest trading session, marking a +1.11% move from the prior day....

There's no need to panic....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

WASHINGTON (dpa-AFX) - Allergan Aesthetics, part of AbbVie (ABBV), on Friday said the European Commission approved Boey for the temporary improvement of moderate to severe glabellar lines, or frow......

ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31....

AbbVie and Baxter both flashed the same bullish technical signal this month, but one golden cross signals genuine momentum while the other masks a fundamentally broken business. Knowing which is which could protect your retirement income from a costly mistake....

Wer langfristig ein passives Einkommen aufbauen möchte, sollte auf Unternehmen setzen, deren Dividenden auch in wirtschaftlich anspruchsvollen Zeiten als verlässlich gelten. Besonders attraktiv sind Aktien von Konzernen mit stabilen Geschäftsmodellen, soliden Finanzen und einer langjährigen Historie kontinuierlich steigender Ausschüttungen. Drei Unternehmen, die diese Kriterien erfüllen und sich als langfristige Depotbausteine eignen, sind AbbVie, Enbridge und […] The post Dividenden-Aktien: 3 Titel für die Ewigkeit first appeared on sharedeals.de....

AbbVie, Enbridge, and Coca-Cola pay high dividends and are the types of stocks that investors can buy and forget about....